Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa

Inclusion Criteria: * Healthy infants born after a normal gestation period (\>=36 weeks), between 5 and 10 weeks of age at Dose 1 with confirmed negative HIV status of the subject's mother. * Written informed consent was obtained from the parent/guardian of the subject before study entry. Exclusion Criteria: * History of allergic disease/polio disease, * Confirmed or suspected immunosuppressive or immunodeficient condition, * Clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator, * Received treatment prohibited by the protocol. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.